A5089652964- Particle physics theoretical and experimental studies
- Quantum Chromodynamics and Particle Interactions
- High-Energy Particle Collisions Research
- Renal Transplantation Outcomes and Treatments
- Antibiotics Pharmacokinetics and Efficacy
- Pharmacological Effects and Toxicity Studies
- HIV/AIDS drug development and treatment
- Particle Detector Development and Performance
- Black Holes and Theoretical Physics
- Particle Accelerators and Free-Electron Lasers
- Neutrino Physics Research
- Cytomegalovirus and herpesvirus research
- Computational Physics and Python Applications
- Pneumocystis jirovecii pneumonia detection and treatment
- Organ Transplantation Techniques and Outcomes
- Medical Imaging Techniques and Applications
- Drug Transport and Resistance Mechanisms
- Antifungal resistance and susceptibility
- HIV/AIDS Research and Interventions
- Pneumonia and Respiratory Infections
- Hepatitis C virus research
- COVID-19 Clinical Research Studies
- Antibiotic Resistance in Bacteria
- Transplantation: Methods and Outcomes
- HIV Research and Treatment
Centre Hospitalier Universitaire de Rennes
2016-2025
Hôpital Pontchaillou
2016-2025
CIC Rennes
2015-2024
Institut de Recherche en Santé, Environnement et Travail
2016-2024
Université de Rennes
2013-2024
Inserm
2015-2024
École des Hautes Études en Santé Publique
2019-2024
Fédération Hospitalo-Universitaire, Paris Center for Microbiome Medicine
2023-2024
Laboratoire de Biophotonique et Pharmacologie
2024
Sorbonne Université
2011-2023
A rapid high-performance liquid chromatography-tandem mass spectrometry (LC-MS/MS) assay was developed for the routine quantification of colistins and B their prodrugs, colistin methanesulfonate (CMS) CMS B, respectively, in human plasma urine by using polymyxin B1 as internal standard (IS). concentrations were determined indirectly subtracting biological samples from whole after sample treatment with sulfuric acid order to hydrolyze into colistin. After extraction on a solid-phase column,...
Abstract Introduction As a result of drug sequestration and increased volume distribution, the extracorporeal membrane oxygenation (ECMO) procedure might lead to decrease in concentrations during patient’s treatment. The aim this study was evaluate sedative, antibiotic immunosuppressive loss ECMO circuit using ex-vivo in-vitro experiments. Methods Blood propofol, midazolam, cyclosporine vancomycin were measured an primed with whole human blood, compared controls stored polypropylene tubes....
Nirmatrelvir/ritonavir (Paxlovid) consists of a peptidomimetic inhibitor (nirmatrelvir) the SARS-CoV-2 main protease and pharmacokinetic enhancer (ritonavir). It is approved for treatment mild-to-moderate COVID-19. This combination nirmatrelvir ritonavir can mediate significant complex drug-drug interactions (DDIs), primarily due to component. Indeed, inhibits metabolism through cytochrome P450 3A (CYP3A) leading higher plasma concentrations longer half-life nirmatrelvir. Coadministration...
Abstract Background The antibiotic management of staphylococcal bone and joint infection usually relies on rifampin associated with another for susceptible strains. appropriate dose remains unclear diverges in international recommendations. 543 patients were randomized, 530 included the Intent-to-Treat analysis 327 per-protocol analysis. Methods We performed an open-label, controlled, noninferiority trial to compare a daily 10 mg/kg (Low-dose) qd 20 (High-dose, divided 10mg/kg bid high BMIs)...
Tacrolimus (TAC) is the cornerstone of immunosuppressive regimen in liver transplantation (LT). Its pharmacokinetics characterized by a high interpatient and intrapatient variability (IPV) leading to an unpredictable dose-response relationship. The aim our study was evaluate impact TAC IPV on graft patient outcomes after LT.We retrospectively analyzed 812 LT recipients treated with TAC. concentrations estimated calculating coefficient variation (CV) whole blood trough concentrations....
The efficacy of nirmatrelvir-ritonavir (NR; Paxlovid, Pfizer, New York, NY) to decrease the risk progression severe COVID-19 in high-risk patients has been demonstrated. However, evidence infected kidney transplant recipients (KTRs) is lacking. Moreover, NR significant and potentially harmful interactions with calcineurin inhibitors (CNIs).In this single-center retrospective study, we included all KTRs treated from April 28 June 3, 2022. A standard management strategy CNI dose adaptation...
This study aimed at exploring the link among individual concentrations, pharmacokinetic parameters, and probability of relapse after de-escalation in a real-world prospective cohort patients with inflammatory bowel disease (IBD) who underwent infliximab treatment de-escalation. Ninety-one were included. A time-varying compartment model was used to estimate parameters trough concentrations. Cox implemented explore influencing Volume, clearance, before linked risk univariate step. Independent...
Nirmatrelvir/ritonavir is a promising option for preventing severe COVID-19 in solid organ transplant recipients with SARS-CoV-2 infection. However, concerns have arisen regarding potential drug interactions calcineurin inhibitors (CNI). This two-phase multicentre retrospective study, involving 113 patients on tacrolimus and 13 cyclosporine A, aimed to assess the feasibility outcomes of recommendations issued by The French societies transplantation (SFT) pharmacology (SFPT) CNI management...